The treatment of pelvic inflammatory disease

Rees, Elisabeth

doi:10.1016/0002-9378(80)91105-9

Cited by 65 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study population of women attending outpatient clinics with known risk factors for STI was, however, similar to those of the studies from the 1980s. The point estimate for the relative risk of PID in women who had chlamydia at baseline compared with those who did not (2.5, 95% CI 1.6, 4.1) is similar to that obtained from the study by Rees [156].…”

Section: Risk Of Female Reproductive Tract Morbidity Resulting From Csupporting

confidence: 72%

“…In the study by Rees [156], the relative risk of PID in gonorrhoea-treated women with chlamydia compared to those without chlamydia at baseline was 2.5 (95% CI 0.7, 8.9). Thus, the risk of PID is higher in chlamydia positive than chlamydia negative women but the confidence intervals are wide because of the small study size.…”

Section: Risk Of Female Reproductive Tract Morbidity Resulting From Cmentioning

confidence: 98%

“…All were conducted in sexually transmitted diseases clinics amongst women at high risk of PID with short follow up periods. In two studies, women were coinfected with gonorrhoea and chlamydia [156,157] and in one study they were partners of men with nongonococcal urethritis [158]. PID was ascertained in women treated with antibiotics that were active against gonorrhoea but not chlamydia, or received placebo.…”

Section: Risk Of Female Reproductive Tract Morbidity Resulting From Cmentioning

confidence: 99%

“…The contribution of chlamydia control activities cannot be disentangled from other factors including antibiotic use, health promotion activities and other changes in sexual health status. The incidence of clinical PID following asymptomatic NAAT-detected chlamydia in women in the general population is probably lower (9%, 95% CI 4, 19% in 1 study [133]) than PID in symptomatic women with chlamydia infection detected by culture (12-30% in 3 studies [156][157][158]). The risk of PID from any cause in women with chlamydia infection compared to those without remains strong.…”

Section: Reproductive Tract Complications Of Chlamydia Infection In Wmentioning

confidence: 89%

See 3 more Smart Citations

Opportunistic testing for urogenital infection with Chlamydia trachomatis in south-western Switzerland, 2012: a feasibility study

et al. 2015

View full text Add to dashboard Cite

The feasibility of opportunistic screening of urogenital infections with Chlamydia trachomatis was assessed in a cross-sectional study in 2012, in two cantons of south-western Switzerland: Vaud and Valais. Sexually active persons younger than?30 years, not tested for C. trachomatis in the last three months, were invited for free C. trachomatis testing by PCR in urine or self-applied vaginal swabs. Of 2,461 consenting participants, 1,899 (77%) were women and all but six (0.3%) submitted a sample. Forty-seven per cent of female and 25% of male participants were?younger than?20 years. Overall, 134 (5.5%) of 2,455 tested participants had a positive result and were followed up. Seven per cent of all candidates for screening were not invited, 10% of invited candidates were not eligible, 15% of the eligible candidates declined participation, 5% of tested participants testing positive were not treated, 29% of those treated were not retested after six months and 9% of those retested were positive for C. trachomatis. Opportunistic C. trachomatis testing proved technically feasible and acceptable, at least if free of charge. Men and peripheral rural regions were more difficult to reach. Efforts to increase testing and decrease dropout at all stages of the screening procedure are necessary.

show abstract

Section: Risk Of Female Reproductive Tract Morbidity Resulting From Csupporting

confidence: 72%

Section: Risk Of Female Reproductive Tract Morbidity Resulting From Cmentioning

confidence: 98%

Section: Risk Of Female Reproductive Tract Morbidity Resulting From Cmentioning

confidence: 99%

Section: Reproductive Tract Complications Of Chlamydia Infection In Wmentioning

confidence: 89%

See 2 more Smart Citations

Opportunistic testing for urogenital infection with Chlamydia trachomatis in south-western Switzerland, 2012: a feasibility study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…trachomatis infections are often asymptomatic and can cause pelvic inflammatory disease (PID), cervicitis, salpingitis, urethritis, and postpartum endometritis (3,18,27,29). Infertility and ectopic pregnancy are complications of untreated PID leading to billions of dollars in direct and indirect healthcare costs (10).…”

mentioning

confidence: 99%

Comparison of the APTIMA CT and GC Assays with the APTIMA Combo 2 Assay, the Abbott LCx Assay, and Direct Fluorescent-Antibody and Culture Assays for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae

et al. 2004

View full text Add to dashboard Cite

Treatment of Sexually Transmitted Chlamydial Infections

Sanders¹

1986

JAMA

View full text Add to dashboard Cite

Tetracycline hydrochloride, 500 mg orally four times a day for seven days, remains the treatment of choice for C trachomatis infections in men and nonpregnant women. Either erythromycin, 500 mg orally four times daily for seven days, or an equivalent dosage of another erythromycin product is an alternative treatment for patients who cannot tolerate tetracycline and for pregnant women. These two treatment regimens can be generalized to include nongonococcal urethritis and mucopurulent cervicitis. However, other treatment regimens that are effective against C trachomatis may not be effective for treating nongonococcal urethritis or mucopurulent cervicitis not caused by C trachomatis. The optimal treatment for pregnant women with C trachomatis infections and women with acute PID has not been established. Additional treatment trials with both groups of patients are needed to determine the effectiveness of antimicrobial agents in addition to those currently used, to establish the appropriate dose of each antimicrobial agent, and to clarify the appropriate duration of treatment. All individuals who are sexual partners of patients with nongonococcal urethritis, mucopurulent cervicitis, and acute PID (within the 30 days prior to onset of their symptoms or time of positive clinical evaluation findings) should be examined for sexually transmitted disease and treated promptly with a regimen effective against uncomplicated gonorrhea and chlamydial infections. Prompt treatment of sexual partners reduces the rate of treatment failure due to reinfection, reduces the transmission of infection, and reduces the frequency of occurrence of adverse sequelae of infection.

show abstract

The treatment of pelvic inflammatory disease

Cited by 65 publications

References 8 publications

Opportunistic testing for urogenital infection with Chlamydia trachomatis in south-western Switzerland, 2012: a feasibility study

Opportunistic testing for urogenital infection with Chlamydia trachomatis in south-western Switzerland, 2012: a feasibility study

Comparison of the APTIMA CT and GC Assays with the APTIMA Combo 2 Assay, the Abbott LCx Assay, and Direct Fluorescent-Antibody and Culture Assays for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae

Treatment of Sexually Transmitted Chlamydial Infections

Contact Info

Product

Resources

About